Lipid OA2 is an ionizable cationic lipid that has been used in the generation of single-component lipid nanoparticles (LNPs) for the delivery of siRNA.1 LNPs containing lipid OA2 and siRNA targeting the gene encoding suppressor of cytokine signaling 1 (Socs1) decrease Socs1 expression by approximately 50% in isolated mouse bone marrow dendritic cells (BMDCs). Vaccination with ovalbumin-induced isolated mouse BMDCs transfected with LNPs composed of lipid OA2 and Socs1-targeting siRNA increases survival and decreases tumor volume in a B16-OVA murine melanoma model.

Compound 11 (EBP inhibitor) is a selective orally bioavailable, brain-penetrant emopamil binding protein (EBP) inhibitor with EC50 of 44 nM. Compound 11 enhances the formation of oligodendrocytes in human cortical organoids.

Lung endothelium-targeted Lipid-1 is used in pulmonary endothelium targeted mRNA delivery. Lung endothelium-targeted Lipid-1 formulated nanoparticle, Lung-LNP (LuLNP) is capable of delivering therapeutic mRNA cargo for vascular repair in influenza infection.

CRT0066101 is a PRKDs inhibitor. CRT0066101 suppressed the proliferation and migration of four bladder cancer cell lines in vitro. CRT0066101 blocked tumor growth in a mouse flank xenograft model of bladder cancer. CRT0066101 treatment or PKD2 silencing arrested bladder cancer cells at the G2/M phase, the arrest being accompanied by decreases in the levels of cyclin B1, CDK1 and phospho-CDK1 (Thr161) and increases in the levels of p27Kip1 and phospho-CDK1 (Thr14/Tyr15). CRT0066101 suppresses bladder cancer growth by inhibiting PKD2 through induction of G2/M cell cycle arrest, leading to the blockade of cell cycle progression.

HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM.

PF-CBP1, also known as PF-06670910, is potent and highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) that down regulates targets of CBP in macrophages primary neurons.

GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM.

NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research.

Phylloflavan is an antileishmanial agent with an intracellular EC50 of 3.2 nM in RAW 264.7 cells. Phylloflavan also inhibits the cytopathic effect of encephalomyocarditis virus on L929 fibroblast cells (38 U/mL).

Benzamide is a small molecule Magmas inhibitor (SMMI). Magmas is mitochondria associated，granulocyte-macrophage colony stimulating factor signaling molecule，as well as a GM-CSF inducible gene in myeloid cells. Magmas-IN-1 inhibits Magmas and modulates mitochondrial function. Magmas-IN-1 also inhibits proliferation in yeast at 4 μM.

VT-105 is a potent and selective TEAD Auto-palmitoylation inhibitor that Inhibits Proliferation and Tumor Growth of NF2-deficient Mesothelioma. VT105 is a more soluble analog of VT104.

AP1189 is a biased agonist at receptors MC1 and MC3. AP1189 reduced cytokine release, an effect reliant on both MC1 and MC3 as evident from the use of Mc1r(-/-) and Mc3r(-/-) macrophages. No melanogenesis was induced by AP1189 in B16-F10 melanocytes. In vivo, oral AP1189 elicited anti-inflammatory actions in peritonitis and, upon administration at the peak of inflammation, accelerated the resolution phase by ∼3-fold.

HaloPROTAC-E is a novel HaloPROTAC potent degrader, inducing reversible degradation of two endosomally localized proteins, SGK3 and VPS34, with a DC50 of 3-10 nM, remarkably selective inducing only degradation of the Halo tagged endogenous VPS34 complex (VPS34, VPS15, Beclin1, and ATG14) and no other proteins were significantly degraded.

Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp.

Stilbamidine dihydrochloride is a blocker of neuromuscular transmission and axonal conduction. It is used to study the distribution of the drug in the organs and tissues of rats following intravenous injection.

MCU-i11 is a novel negative modulator of the MCU, binding MICU1 and impairing muscle cell growth.

GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.

Pyrithione, a Transition metal complexe, is a zinc ionophore that causes increased zinc levels within mammalian cells. Pyrithione has potent bactericidal and anti-fungal activity.

SLU-PP-1072 is a novel Selective ERRα/γ Inverse Agonist, Inhibiting the Warburg Effect and Inducing Apoptosis in Prostate Cancer Cells.

LMTK3-IN-1 (compound C28) is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM)，that acts by degrading LMTK3 via the ubiquitin-proteasome pathway. LMTK3-IN-1 shows anticancer activity in a variety of cancer cell lines and in vivo BC mouse models. LMTK3-IN-1 induces apoptosis in BC cell lines at 10-20 μM.

PT-179 is a new orthogonal immunomodulatory drug (IMiD) derivative that binds CRBN but does not induce degradation of off-target proteins. PT-179 potently degrades proteins fused to SD40 at either the N or C terminus.

PSB-1901 is a potent A2B adenosine receptor (A2BAR) antagonist with Kis of 0.0835 nM and 0.131 nM for human and mouse A2BARs respectively. PSB-1901 can be used for the research of cancer.

2-Amino-8-oxononanoic acid HCl is a biochemical

2-Fluorofumarate is a bioactive chemical.

Protonstatin-1 is a selective small-molecule inhibitor of PM H+ -ATPase activity that inhibits auxin transport.

SBFI-26 (SBFI26) is a small molecule inhibitor of epidermal- and brain-specific FABP5 and FABP7 that effectively increases anandamide signaling; dose-dependently reduces mechanical hyperalgesia in vivo, demonstrates significant analgesic and anti-inflammatory properties; also suppresses the malignant progression of castration resistant prostate cancer cells by competitively binding to oncogenic FABP5.

IM176OUT05 is a high solubility biguanide. IM176OUT05 activates stem cell metabolism, promotes hair regrowth and increases stemness induction and maintenance during the pluripotent stem cell generation process. IM176OUT0 inhibits mitochondrial electron transport chain (ETC) activity with an IC50 of 3.2 μM.

5-HT2A receptor agonist-3 is the most selective agonist for the human 5-HT2A receptor yet discovered, with a Ki of 2.5 nM, and with 124-fold selectivity for 5-HT2A over the structurally similar 5-HT2C receptor.

β-pBrPh-Glc is a small-molecule ice recrystallization inhibitor. β-pBrPh-Glc can control the rate and extent of intracellular ice recrystallization in the nuclei over a broad range of subzero temperatures. β-pBrPh-Glc is an important tool to improve the recovery and function of cryopreserved cells and tissues.

anti-dengue virus infections;

MMP-9-IN-7 is a potent MMP9 inhibitor with an IC50 of 0.52 μM in proMMP9/MMP3 P126 activation assay. MMP-9-IN-7 is extracted from patent WO2012162468 (example 59), and can be used for MMP9/MMP13 mediated syndrome research.

B-Raf IN 14 (Comp 25) is a BRAF inhibitor with IC50 value of 11.08 μM, which can be used in cancer-related research.

PI3Kα-IN-11 is a potent PI3Kα inhibitor with anticancer activity.

useful for preventing or treating obesity, dyslipidemia, fatty liver or diabetes;

Mycobacterium tuberculosis shikimate kinase inhibitors

inhibitor of the human soluble epoxide hydrolase

neuroprotective effects; altering the lifespan of a eukaryotic organism;

TCRS-417 (T417) is a small molecule compound capable of docking to the interface between PBX1 and its cognate DNA target sequence, effectively interfering with PBX1-DNA interaction. TCRS-417 can be used in the research of cancer, developmental disorders, inflammatory disorders, autoimmune diseases or neurodegenerative diseases.

calcium channel antagonist

inhibitor of Ral GTPases

Inhibitor of UDP-galactopyranose mutase;

CRT0063465 is a novel Ligand of Human PGK1 and Stress Sensor DJ1, Modulating the Shelterin Complex and Telomere Length Regulation.

Protein tyrosine Phosphatase 1B (PTP1B) agonist

inhibitor of flavivirus replication

altering the lifespan of a eukaryotic organism; anti-viral;

Enterobactin is a high affinity siderophore that acquires iron for microbial systems.

Clenpirin is a bio-active chemical.

Naphthol AS-TR Phosphate disodium is a water-soluble dye commonly used as an enzymatic substrate in various biochemical assays to detect alkaline phosphatase activity. Naphthol AS-TR Phosphate disodium has unique chemical properties that allow it to be hydrolyzed by alkaline phosphatase, forming a colored product that can be detected spectrophotometrically. This makes it a useful tool for monitoring enzyme activity in biological samples such as serum or urine.

Imiloxan hydrochloride is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan hydrochloride has the potential for acute kidney injury research.

(R)-(-)-α-Methylhistamine dihydrobromide is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM. (R)-(-)-α-Methylhistamine dihydrobromide can enhance memory retention, attenuates memory impairment in rats.

PTP1B-IN-4 is a non-competitive allosteric inhibitor of the protein tyrosine phosphatase PTP1B, with an IC50 of 8 μM. PTP1B-IN-4 is potentail for the research of obesity and diabetes.

10-Formylfolic acid is a potent inhibitor of dihydrofolate reductase.

OTUB1/USP8-IN-1 is a potent dual OTUB1/USP8 inhibitor with IC50 values of 0.17 and 0.28 nM for OTUB1 and USP8, respectively. OTUB1/USP8-IN-1 can be used in research of cancer.

GoSlo-SR-5-69 is a potent activator of large conductance Ca2+-activated K+ (BK) channels, with an EC50 of 251 nM.

Use of Vocacapsaicin hydrochloride Vocacapsaicin (CA-008) hydrochloride, a prodrug of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin hydrochloride can provide meaningful and long-lasting pain relief.

UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2.

AM4085 is a potent, orally bioavailable lectin domain of FmLH antagonist with IC50 of 0.19 uM.

BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase and the F1Fo-ATP synthase.

BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro.

BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC.

BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae.

BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species.

COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL.

Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides.

CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens.

D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope.

DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis.

EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load.

GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites.

GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM).

GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM).

HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL).

JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation.

JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM).

JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA.

JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co

JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM.

JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene.

LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities.

MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics.

MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM.

MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively.

MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3.

ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases.

NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM.

NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains.

OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo.

PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus.

SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors.

Savirin (S. aureus virulence inhibitor) is a small molecule inhibitor inhibiting agr quorum sensing in S. aureus by blocking the transcriptional function of AgrA.

SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro.

SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM.

SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo.

SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity.

TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively.

TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063  μg/ml).

TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM.

TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics.

TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously iden

TXY436 is an N-Mannich base derivative and FtsZ-directed prodrug of PC190723, TXY436 is effective against S. aureus can also target Gram-negative bacteria, such as Escherichia coli.

TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus.

VU0026921 is a small molecule modulator of metal homeostasis in gram-positive pathogens, disrupts metal homeostasis in multiple Gram-positive bacteria, leading to increased reactive oxygen species and cell death.

NPP-669 (NPP669) is an orally bioavailable cidofovir (CDV) analogue and prodrug, has increased lipophilicity, improved oral absorption, reduced nephrotoxicity, increased cellular uptake, and increased activity against several dsDNA viruses compared to CDV

AG-7404 (AG7404) is a potent, irreversible inhibitor of picornaviral 3C protease, exhibits EC50 values of 80-674 nM against a large panel of programmatically important poliovirus strains.

SJW-2C-227 is a broad-spectrum anti-viral compound that target enterovirus 2C potein, inhibits 2C ATPase activity, exhibits anti-viral activity of SJW-2C-227 with an EC50 of 1.7 µM against EVA71 and 0.52 µM against EV-D68.

ZHSI-1 is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

ZHSI-1 hydrochloride is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

Cotransin CT8 (CT-08) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

Cotransin CT9 (CT-09) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins.

PS3061 (PS 3061) is a substrate-selective co-translational translocation inhibitor, modulates SEC61 translocon and inhibits both DENV and ZIKV virion production and replication.

CWHM-974 is a fluphenazine derivative with antifungal activity against Candida albicans, significantly reduces susceptibility to multidrug transporter-mediated resistance.

FC12406 is a highly potent and broadly active antifungal agent, has MIC of 0.2 ug/mL against Candida albicans.

MMV688766 (MMV 688766) is a small molecule displaying broad-spectrum fungicidal activity through perturbation of lipid homeostasis, inhibits the growth of four geographically distinct C. auris clades with MIC80 of 12.5-50 uM.

NP-BTA is a potent, allosteric inhibitor of C. albicans glutaminyl-tRNA synthetase Gln4 with ITC KD of 180 nM and IC50 of 108 nM, strongly inhibits Candida albicans growth.

NPD6433 is a novel broad-spectrum antifungal agent with MIC <10 ug/mL against C. albicans, Candida glabrata, Candida auris, and C. neoformans, inhibits Fas1 enoyl reductase activity.

YU385599 is a high-affinity inhibitor of fungal pantothenate kinase (PanK), exhibits excellent activity against the human pathogens Candida albicans, C. glabrata, and C. parapsilosis.

DF-006 is a small molecule, orally active Alpha-kinase 1 (ALPK1) agonist, activates ALPK1 and stimulates host innate immunity locally in liver, DF-006 enacts potent anti-HBV responses in mouse models of HBV and in primary human hepatocytes.

E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.

Neracorvir is a potent anti-HBV agent, targets HBV surface antigen.

SAG-524 (SAG524) is a potent and orally bioavailable small molecule inhibitor of HBV replication, reduces HBsAg and HBV-DNA (IC50 = 0.92 nM and 1.4 nM) by destabilizing HBV-RNA.

ZINC20451377 is a small molecule that binds to hepatitis B surface antigen (HBsAg) with high affinity (Kd=65.3 nM), reduces HBsAg levels and HBV virion secretion in cell culture model for HBV.

GS-9770 is a potent, selective, non-peptidomimetic and orally active HIV protease inhibitor with Ki(app) value of 0.16 nM (recombinant HIV-1 PR).

GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI).

GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM).

iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.

JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells.

PAV-206 is a novel potent antiretroviral chemotype that inhibits HIV-1 replication with EC50 of 34 nM in HIV-1-infected MT-2 T cells, and 75 nM in HIV-1-infected peripheral blood mononuclear cells (PBMCs), inhibits HIV-1 replication by interfering with HI

SO-7g is a novel highly active HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), exhibits moderate to excellent potency against wild-type HIV-1 with EC50 of 5.3 nM.

TX-1918 (TX1918) is a specific inhibitor of HIV-1 capsid assembly taregting the C-terminal domain of HIV-1 capsid (CA CTD) with IC50 of 3.81 uM, inhibits viral replication (EC50=15.16 μM) and inhibits CA assembly in vitro.

VTD227 is a small molecule Vpr-targeting HIV-1 inhibitor, directly binds to Vpr with Kd of 8.8 uM, inhibits HIV-1 replication in monocyte-derived macrophages (MDM) with IC50 of 0.78 uM.

ANA-0 is a potent inhibitor against the replication of multiple subtypes of influenza A virus, interacts with N-terminal domain of the PA subunit with Kd value of 1.1 uM, and impedes it's endonuclease activity.

dEF3122 is a highly potent small molecule inhibitor of influenza virus replication with IC50 of 3 nM in neuraminidase activity assays, taregts NEET family of protein NAF-1.

ING-1466 is an orally active entry inhibitor of influenza A viruses (IAVs) with EC50 of 0.18 uM against IAV H1N1 (PR8-NS1-Gluc), binds to hemagglutinin (HA) and blocks HA-mediated viral infection.

JJ3297 is a potent antagonist of influenza virus non-structural protein 1 (NS1), strongly restores IFN-β mRNA levels and inhibits viral replication in MDCK cells (IC50=0.8 uM).

NSC125044 is a small molecule inhibitor of the influenza virus protein NS1, inhibits different influenza strains cultured in MDCK-UK cells with IC50 of 7-12 uM.

AWE402 (AWE-402) is a small molecule inhibitor targeting M. tuberculosis cytochrome bcc-aa3 of the electron transport chain (ETC), shows MIC value of 5 nM activity against Mycobacterium tuberculosis H37Rv.

CK-2-63 is a potent first-in-class M. tuberculosis cytochrome bd (cyt bd) inhibitor, demonstrates growth suppression of M. tuberculosis H37Rv with IC50 of 3.7 uM.

CWHM-117 is potent nanomolar inhibitor of the Plasmodium aspartic proteases PM-II and PM-IV with IC50 of 4 and 15 nM respectively, exhibits IC50 of 463 nM in the Pf 3D7 infected RBC assays.

DNDI-6174 is a highly potent inhibitor of Leishmania cytochrome bc1 complex activity, shows broad activity against a panel of representative visceral leishmaniasis clinical isolates from various sources (EC50=10-360 nM).

DSM161 (DSM 161) is a high potent A. baumannii DHODH (AbDHODH) inhibitor, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DSM186 (DSM 186) is a high potent A. baumannii DHODH (AbDHODH) inhibitor with IC50 of 28 nM, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

ELQ-331 (ELQ331) is an alkoxycarbonate prodrug of antimalarial compound ELQ-300 (P. falciparum cytochrome bc1 complex inhibitor), shows P. falciparum IC50 of 6 nM.

Genz-667348 (Genz667348) is a potent, selective P. falciparum DHODH inhibitor with IC50 of 22, 14 and 42 nM for PfDHODH, PbDHODH and PvDHODH, respectively.

Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite s

KNX-002 (KNX002) is a potent, specific inhibitor of Toxoplasma gondii class XIV myosin TgMyoA, inhibits TgMyoA ATPase activity with IC50 of 2.8 uM, shows little to no effect on any of the vertebrate myosins.

KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.

MBX-2366 (ISG-21) is a potent and specific antimalarial compound with IC50 of 3 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=2 nM) to quantitatively abolish parasite-induced permeability change